Loading...
•
Dec 31, 2022
ICU Medical Q4 2022 Earnings Report
Announced fourth quarter 2022 results and provided fiscal year 2023 guidance.
Key Takeaways
ICU Medical's fourth quarter 2022 revenue was $578.0 million, compared to $340.5 million in the same period last year. The adjusted diluted earnings per share for the fourth quarter of 2022 was $1.60 as compared to $1.82 for the fourth quarter of 2021.
Fourth quarter 2022 revenue was $578.0 million, compared to $340.5 million in the same period last year.
GAAP gross profit for the fourth quarter of 2022 was $174.9 million, as compared to $127.5 million in the same period last year.
Adjusted diluted earnings per share for the fourth quarter of 2022 was $1.60 as compared to $1.82 for the fourth quarter of 2021.
Adjusted EBITDA was $96.4 million for the fourth quarter of 2022 as compared to $64.2 million for the fourth quarter of 2021.
ICU Medical
ICU Medical
ICU Medical Revenue by Segment
Revenue by Segment
Consumables Revenue
CapyFin.comInfusion Systems Revenue
CapyFin.com Forward Guidance
For Fiscal Year 2023, the Company estimates GAAP net loss to be in the range of $(73) to $(37) and GAAP diluted loss per share estimated to be in the range of $(3.00) to $(1.50). For the Fiscal Year 2023, the Company expects adjusted EBITDA to be in the range of $375 million to $425 million, and adjusted diluted EPS to be in the range of $5.75 to $7.25.
Positive Outlook
- The Company expects adjusted EBITDA to be in the range of $375 million to $425 million for fiscal year 2023.
- The Company expects adjusted diluted EPS to be in the range of $5.75 to $7.25 for fiscal year 2023.
Challenges Ahead
- The Company estimates GAAP net loss to be in the range of $(73) to $(37) for fiscal year 2023.
- GAAP diluted loss per share estimated to be in the range of $(3.00) to $(1.50) for fiscal year 2023.
Revenue & Expenses
Visualization of income flow from segment revenue to net income